Reported Earlier, Roivant Announced That Results From The Phase 2 Phocus Study Of Mosliciguat In Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease (Ph-ild) Will Be Presented At The European Respiratory Society International Congress 2026 On Tuesday, September 8, 2026
Share
Why It Matters
Roivant is sharing results from a medicine study at a big doctor conference next year. When companies present study results at important conferences, it tells us whether their new medicines are working the way they hoped.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.